Last reviewed · How we verify
OXABOLONE CIPIONATE
OXABOLONE CIPIONATE is a oxabolone cipionate drug. It is currently in Phase 2 development.
Oxabolone cipionate is thought to work by interacting with a specific biological target, but its exact mechanism of action is not well understood.
Oxabolone cipionate is a small molecule medication. It is also known by several other names, including Cipionate d'oxabolone, Cipionato de oxabolona, and FI 5852.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | OXABOLONE CIPIONATE |
|---|---|
| Drug class | oxabolone cipionate |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and oxabolone cipionate is a key that fits into one of those locks. When it binds to the lock, it can either turn the lock on or off, depending on the type of lock and the key's shape. This can affect how cells behave and communicate with each other.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OXABOLONE CIPIONATE CI brief — competitive landscape report
- OXABOLONE CIPIONATE updates RSS · CI watch RSS
Frequently asked questions about OXABOLONE CIPIONATE
What is OXABOLONE CIPIONATE?
How does OXABOLONE CIPIONATE work?
What drug class is OXABOLONE CIPIONATE in?
What development phase is OXABOLONE CIPIONATE in?
Related
- Drug class: All oxabolone cipionate drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing